Literature DB >> 20610348

Multiple sclerosis: risk factors, prodromes, and potential causal pathways.

Sreeram V Ramagopalan1, Ruth Dobson, Ute C Meier, Gavin Giovannoni.   

Abstract

Multiple sclerosis (MS) is a common, complex neurological disease. The precise aetiology of MS is not yet known, although epidemiological data indicate that both genetic and environmental factors are important. The evidence that the environment acts long before MS becomes clinically evident is well established and suggests the existence of a prodromal phase for the disease. The increasing incidence of MS emphasises the need for strategies to prevent this chronic disorder, and the possibility of a prodrome indicates a window of opportunity to potentially reverse early disease processes before clinical disease becomes evident. Studying a prodrome requires techniques other than clinical observation such as monitoring endophenotypes that result from associated risk factors. However, our current knowledge of causal pathways and endophenotypes in MS is limited. Identifying and studying individuals with a high risk of developing the disease provides a powerful opportunity to understand the MS causal cascade and is highly relevant to strategies that are aimed at preventing this debilitating disease. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20610348     DOI: 10.1016/S1474-4422(10)70094-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  132 in total

1.  Chronic cerebrospinal venous insufficiency in multiple sclerosis: a historical perspective.

Authors:  Michael D Dake; Robert Zivadinov; E Mark Haacke
Journal:  Funct Neurol       Date:  2011 Oct-Dec

2.  Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis.

Authors:  Magdalena Janina Laska; Tomasz Brudek; Kari Konstantin Nissen; Tove Christensen; Anné Møller-Larsen; Thor Petersen; Bjørn Andersen Nexø
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Chronic cerebrospinal venous insufficiency as a cause of multiple sclerosis: controversy and reality.

Authors:  Claudiu I Diaconu; Devon Conway; Robert J Fox; Alexander Rae-Grant
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-04

Review 4.  Epigenetics of multiple sclerosis: an updated review.

Authors:  Cem İsmail Küçükali; Murat Kürtüncü; Arzu Çoban; Merve Çebi; Erdem Tüzün
Journal:  Neuromolecular Med       Date:  2014-03-21       Impact factor: 3.843

5.  Combined upper limb and breathing exercise programme for pain management in ambulatory and non-ambulatory multiple sclerosis individuals: part II analyses from feasibility study.

Authors:  Tanja Grubić Kezele; Matea Babić; Tamara Kauzlarić-Živković; Tamara Gulić
Journal:  Neurol Sci       Date:  2019-08-17       Impact factor: 3.307

Review 6.  Perimenopause as a neurological transition state.

Authors:  Roberta D Brinton; Jia Yao; Fei Yin; Wendy J Mack; Enrique Cadenas
Journal:  Nat Rev Endocrinol       Date:  2015-05-26       Impact factor: 43.330

Review 7.  CD46 in innate and adaptive immunity: an update.

Authors:  J Cardone; G Le Friec; C Kemper
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

Review 8.  Immunizations and risk of multiple sclerosis: systematic review and meta-analysis.

Authors:  Mauricio F Farez; Jorge Correale
Journal:  J Neurol       Date:  2011-03-24       Impact factor: 4.849

Review 9.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

10.  Multimodal partial volume correction: Application to [11C]PIB PET/MRI myelin imaging in multiple sclerosis.

Authors:  Elisabetta Grecchi; Mattia Veronese; Benedetta Bodini; Daniel García-Lorenzo; Marco Battaglini; Bruno Stankoff; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.